Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

NCT02209376 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
11
Enrollment
OTHER
Sponsor class

Stopped Sponsor decision to terminate prior to completion to pursue combination therapies.

Conditions

Interventions

Sponsor

University of Pennsylvania

Collaborators